TSVT News and Press, 2seventy bio Inc. From 05/07/24

2024-05-07 13:19:48 ET More on 2seventy bio 2seventy Bio: Maximizing ABECMA's Potential To Fuel A Turnaround 2Seventy Bio, Inc. (TSVT) Q4 2023 Earnings Call Transcript Bristol-Myers posts Q1 beat despite growth headwinds Bristol Myers, 2seventy bio's Abecma a...

2seventy bio, Inc . (Nasdaq: TSVT) will announce its first quarter 2024 financial results on Wednesday, May 8, 2024. A conference call and webcast will be held at 8:00 a.m. ET. Participants can access the conference call live via webcast which will be available on the Investors and Media pa...

2024-04-25 10:00:28 ET More on Health Care Select Sector SPDR XLV: Fundamentals Don't Support Overweighting Health Care XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance BofA watched clients retract $2B last week as the S&P dropped ...

2024-04-25 07:56:55 ET More on Bristol-Myers Squibb Company Is Bristol Myers Squibb A Buy At These Bottom Levels? Bristol-Myers Squibb: Market Pessimism Won't Last Forever Bristol Myers Squibb: Seriously Undervalued At Peak Pessimism (Rating Upgrade) Bristol-...

2024-04-19 06:13:03 ET More on Bristol-Myers Squibb, Gilead, etc. Johnson & Johnson: Buy This Bargain Before It's Gone Bristol-Myers Squibb: Market Pessimism Won't Last Forever Johnson & Johnson (JNJ) Q1 2024 Earnings Call Transcript FDA approves Alvo...

2024-04-08 00:00:02 ET Citigroup analyst issues BUY recommendation for TSVT on April 7, 2024 04:22PM ET. The previous analyst recommendation was Buy. TSVT was trading at $4.92 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analys...

2024-04-06 08:38:09 ET More on Johnson & Johnson Johnson & Johnson: Self-Proclaimed 'Dividend King' Faces Tricky Outlook With Lawsuit And Medtech Tailwinds - Johnson & Johnson May Be Back Johnson & Johnson (JNJ) Barclays 26th Annual Global Healthcare ...

2024-04-05 09:33:47 ET Bristol Myers Squibb ( NYSE: BMY ) said on Friday that the company and 2seventy bio ( NASDAQ: TSVT ) received U.S. FDA approval for Abecma in the treatment of adult patients with relapsed or refractory multiple myeloma.... Rea...

Abecma tripled progression-free survival compared to standard regimens in the Phase 3 KarMMa-3 trial, with a 51% reduction in risk of disease progression or death and a well-established safety profile Expanded approval brings this personalized CAR T cell therapy to more pati...

2024-04-03 17:24:42 ET Gainers: Signature Bank ( OTC:SBNY ) +10% . MacroGenics ( MGNX ) +9% . Simulations Plus ( SLP ) +7% . Annexon ( ANNX ) +6% . 2seventy  ( TSVT ) +5% . Losers: Cadiz ( CDZIP ) -11% . ...